Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Hemophilia Topic Center

Featured Article

News
HAVEN 7 Trial Evaluates Emicizumab Prophylaxis in Infants With Hemophilia A
06/19/2024
Grace Taylor, MS, MA
A study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in infants from birth to age ≤12 months who have hemophilia A without factor VIII inhibitors.
A study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in infants from birth to age ≤12 months who have hemophilia A without factor VIII inhibitors.
A study evaluated the efficacy,...
06/19/2024
First Report Managed Care
News
Factor VIII Market Expected to Grow Over Next 5 Years
05/24/2024
Jolynn Tumolo
The global market for human coagulation factor VIII, which holds significant importance in managing hemophilia A, is poised for substantial growth over the coming years, according to market research firm Quants and Trends.
The global market for human coagulation factor VIII, which holds significant importance in managing hemophilia A, is poised for substantial growth over the coming years, according to market research firm Quants and Trends.
The global market for human...
05/24/2024
First Report Managed Care
News
Study Finds No Treatment-Related Adverse Events in Boys Treated With Purified FIX Concentrate
05/09/2024
Jolynn Tumolo
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX)...
05/09/2024
First Report Managed Care
News
The Impact of Inhibitors on Surgical Management in Patients With Hemophilia
04/04/2024
Hannah Musick
The development of inhibitors in patients with hemophilia poses challenges for achieving perioperative hemostasis and may result in complications and deviations from the surgical plan, highlighting the need for strategies to address inhibitor...
The development of inhibitors in patients with hemophilia poses challenges for achieving perioperative hemostasis and may result in complications and deviations from the surgical plan, highlighting the need for strategies to address inhibitor...
The development of inhibitors in...
04/04/2024
First Report Managed Care
News
Patient Education on AAV Vectors for Hemophilia Essential to Prevent ‘Buyer’s Remorse’
11/10/2023
Jolynn Tumolo
Having long served as the model disorders for the development of gene therapy, hemophilia A (HA) and hemophilia B (HB) are currently benefitting from the role with the emergence of adeno-associated viral (AAV) vectors, according to a review...
Having long served as the model disorders for the development of gene therapy, hemophilia A (HA) and hemophilia B (HB) are currently benefitting from the role with the emergence of adeno-associated viral (AAV) vectors, according to a review...
Having long served as the model...
11/10/2023
First Report Managed Care
News
Changing Trends in Hemophilia Treatment
10/27/2023
Julie Gould
“With other novel therapies (including gene therapy) entering the US market, it is important to document the variability in existing prescribing practices among broad-based cohorts of clinicians,” explain study authors.
“With other novel therapies (including gene therapy) entering the US market, it is important to document the variability in existing prescribing practices among broad-based cohorts of clinicians,” explain study authors.
“With other novel therapies...
10/27/2023
First Report Managed Care
News
Acquired Hemophilia A Treatment Gaps Identified
10/16/2023
Julie Gould
According to a recent study published online in Cureus, “Increasing education about existing AHA guidelines, including available therapies and access to expert care at hemophilia treatment centers, may help improve the outcomes of patients...
According to a recent study published online in Cureus, “Increasing education about existing AHA guidelines, including available therapies and access to expert care at hemophilia treatment centers, may help improve the outcomes of patients...
According to a recent study...
10/16/2023
First Report Managed Care
News
Gene Therapy for Hemophilia: Considering Therapeutic Value, Patient Selection
08/09/2023
Hannah Musick
Authors of a recent review discussed the value of emerging gene therapies for patients with hemophilia, emphasizing that one of the biggest challenges remains the appropriate selection of patients.
Authors of a recent review discussed the value of emerging gene therapies for patients with hemophilia, emphasizing that one of the biggest challenges remains the appropriate selection of patients.
Authors of a recent review...
08/09/2023
First Report Managed Care
News
High Industry Payments to Hemophilia Center Directors May Be Cause for Concern
07/21/2023
Jolynn Tumolo
“Future studies should assess whether high payments, especially among individuals who have responsibility over the success of hemophilia centers and clinics, may result in competition with the interest of the patients at these centers and...
“Future studies should assess whether high payments, especially among individuals who have responsibility over the success of hemophilia centers and clinics, may result in competition with the interest of the patients at these centers and...
“Future studies should assess...
07/21/2023
First Report Managed Care
News
Disparities Between Guideline Recommendations, Implementation of Pharmacokinetic Dosing for Bleeding Disorders
07/17/2023
Julie Gould
Authors of a recent scoping review explored trends in the efficacy and feasibility of implementing pharmacokinetic-guided dosing in clinical practice for patients with bleeding disorders.
Authors of a recent scoping review explored trends in the efficacy and feasibility of implementing pharmacokinetic-guided dosing in clinical practice for patients with bleeding disorders.
Authors of a recent scoping...
07/17/2023
First Report Managed Care
News
First Gene Therapy for Severe Hemophilia A Is Approved
06/29/2023
This approval comes after a safety and effectiveness trial showed that the treatment improved participants’ annualized bleeding rate after 3 years.
This approval comes after a safety and effectiveness trial showed that the treatment improved participants’ annualized bleeding rate after 3 years.
This approval comes after a...
06/29/2023
Population Health
From Population Health

Newsfeed

News
HAVEN 7 Trial Evaluates Emicizumab Prophylaxis in Infants With Hemophilia A
06/19/2024
Grace Taylor, MS, MA
A study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in infants from birth to age ≤12 months who have hemophilia A without factor VIII inhibitors.
A study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in infants from birth to age ≤12 months who have hemophilia A without factor VIII inhibitors.
A study evaluated the efficacy,...
06/19/2024
First Report Managed Care
News
Factor VIII Market Expected to Grow Over Next 5 Years
05/24/2024
Jolynn Tumolo
The global market for human coagulation factor VIII, which holds significant importance in managing hemophilia A, is poised for substantial growth over the coming years, according to market research firm Quants and Trends.
The global market for human coagulation factor VIII, which holds significant importance in managing hemophilia A, is poised for substantial growth over the coming years, according to market research firm Quants and Trends.
The global market for human...
05/24/2024
First Report Managed Care
News
Study Finds No Treatment-Related Adverse Events in Boys Treated With Purified FIX Concentrate
05/09/2024
Jolynn Tumolo
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX)...
05/09/2024
First Report Managed Care
News
The Impact of Inhibitors on Surgical Management in Patients With Hemophilia
04/04/2024
Hannah Musick
The development of inhibitors in patients with hemophilia poses challenges for achieving perioperative hemostasis and may result in complications and deviations from the surgical plan, highlighting the need for strategies to address inhibitor...
The development of inhibitors in patients with hemophilia poses challenges for achieving perioperative hemostasis and may result in complications and deviations from the surgical plan, highlighting the need for strategies to address inhibitor...
The development of inhibitors in...
04/04/2024
First Report Managed Care
News
Patient Education on AAV Vectors for Hemophilia Essential to Prevent ‘Buyer’s Remorse’
11/10/2023
Jolynn Tumolo
Having long served as the model disorders for the development of gene therapy, hemophilia A (HA) and hemophilia B (HB) are currently benefitting from the role with the emergence of adeno-associated viral (AAV) vectors, according to a review...
Having long served as the model disorders for the development of gene therapy, hemophilia A (HA) and hemophilia B (HB) are currently benefitting from the role with the emergence of adeno-associated viral (AAV) vectors, according to a review...
Having long served as the model...
11/10/2023
First Report Managed Care
News
Changing Trends in Hemophilia Treatment
10/27/2023
Julie Gould
“With other novel therapies (including gene therapy) entering the US market, it is important to document the variability in existing prescribing practices among broad-based cohorts of clinicians,” explain study authors.
“With other novel therapies (including gene therapy) entering the US market, it is important to document the variability in existing prescribing practices among broad-based cohorts of clinicians,” explain study authors.
“With other novel therapies...
10/27/2023
First Report Managed Care
News
Acquired Hemophilia A Treatment Gaps Identified
10/16/2023
Julie Gould
According to a recent study published online in Cureus, “Increasing education about existing AHA guidelines, including available therapies and access to expert care at hemophilia treatment centers, may help improve the outcomes of patients...
According to a recent study published online in Cureus, “Increasing education about existing AHA guidelines, including available therapies and access to expert care at hemophilia treatment centers, may help improve the outcomes of patients...
According to a recent study...
10/16/2023
First Report Managed Care
News
Gene Therapy for Hemophilia: Considering Therapeutic Value, Patient Selection
08/09/2023
Hannah Musick
Authors of a recent review discussed the value of emerging gene therapies for patients with hemophilia, emphasizing that one of the biggest challenges remains the appropriate selection of patients.
Authors of a recent review discussed the value of emerging gene therapies for patients with hemophilia, emphasizing that one of the biggest challenges remains the appropriate selection of patients.
Authors of a recent review...
08/09/2023
First Report Managed Care
News
High Industry Payments to Hemophilia Center Directors May Be Cause for Concern
07/21/2023
Jolynn Tumolo
“Future studies should assess whether high payments, especially among individuals who have responsibility over the success of hemophilia centers and clinics, may result in competition with the interest of the patients at these centers and...
“Future studies should assess whether high payments, especially among individuals who have responsibility over the success of hemophilia centers and clinics, may result in competition with the interest of the patients at these centers and...
“Future studies should assess...
07/21/2023
First Report Managed Care
News
Disparities Between Guideline Recommendations, Implementation of Pharmacokinetic Dosing for Bleeding Disorders
07/17/2023
Julie Gould
Authors of a recent scoping review explored trends in the efficacy and feasibility of implementing pharmacokinetic-guided dosing in clinical practice for patients with bleeding disorders.
Authors of a recent scoping review explored trends in the efficacy and feasibility of implementing pharmacokinetic-guided dosing in clinical practice for patients with bleeding disorders.
Authors of a recent scoping...
07/17/2023
First Report Managed Care
News
AHA Voices Concern Over CMS Payment Updates to LTC Hospitals
08/07/2024
The American Hospital Association (AHA) expressed deep concern in response to long-term care (LTC) hospital payment updates finalized by the Centers for Medicare & Medicaid (CMS) on August 1, 2024.
The American Hospital Association (AHA) expressed deep concern in response to long-term care (LTC) hospital payment updates finalized by the Centers for Medicare & Medicaid (CMS) on August 1, 2024.
The American Hospital...
08/07/2024
First Report Managed Care
News
Obesity Linked to Distinct Heart Muscle Abnormalities in Patients With HFpEF, Study Finds
08/05/2024
A recent study published in Nature Cardiovascular Research highlighted the significant impact of severe obesity on myocardial ultrastructure in patients with heart failure with preserved ejection fraction (HFpEF), revealing potential...
A recent study published in Nature Cardiovascular Research highlighted the significant impact of severe obesity on myocardial ultrastructure in patients with heart failure with preserved ejection fraction (HFpEF), revealing potential...
A recent study published in...
08/05/2024
First Report Managed Care
News
New Treatment Options Benefit Patients With Relapsed/Refractory Follicular Lymphoma
08/05/2024
Patients with relapsed/refractory follicular lymphoma tend to have a poorer response and shortened progression-free survival with each subsequent treatment, but new treatment options are emerging.
Patients with relapsed/refractory follicular lymphoma tend to have a poorer response and shortened progression-free survival with each subsequent treatment, but new treatment options are emerging.
Patients with...
08/05/2024
First Report Managed Care
Conference Coverage
Centering Patients Within Value-Based Care
07/30/2024
Asembia 2024 speakers Olivia Banyon and Sean McCabe discuss the concept of value-based care, patient-centered care, clinician well-being, and system workflows to improve the quality of life for patients.
Asembia 2024 speakers Olivia Banyon and Sean McCabe discuss the concept of value-based care, patient-centered care, clinician well-being, and system workflows to improve the quality of life for patients.
Asembia 2024 speakers Olivia...
07/30/2024
First Report Managed Care
News
Sun Exposure Linked With Lower Risk of Follicular Lymphoma
07/30/2024
High sun exposure in warmer months may protect against the development of follicular lymphoma, according to a study published in the journal Cancer Epidemiology, Biomarkers & Prevention.
High sun exposure in warmer months may protect against the development of follicular lymphoma, according to a study published in the journal Cancer Epidemiology, Biomarkers & Prevention.
High sun exposure in warmer...
07/30/2024
First Report Managed Care
News
Updated CDC Recommendation for RSV Vaccination in Older Adults
07/29/2024
The Center for Disease Control and Prevention (CDC) vaccine advisory group updated its recommendation for the use of the respiratory syncytial virus (RSV) vaccine in older adults so that people ages 60 to 74 with certain underlying conditions...
The Center for Disease Control and Prevention (CDC) vaccine advisory group updated its recommendation for the use of the respiratory syncytial virus (RSV) vaccine in older adults so that people ages 60 to 74 with certain underlying conditions...
The Center for Disease Control...
07/29/2024
First Report Managed Care
Bill McElnea
Conference Coverage
Unlocking the Value-Based Care Potential of Health System Specialty Pharmacies
07/26/2024
Asembia 2024 speaker Bill McElnea discusses the role of health system specialty pharmacies in reducing total cost of care, enhancing medication adherence, and improving outcomes under value-based care arrangements.
Asembia 2024 speaker Bill McElnea discusses the role of health system specialty pharmacies in reducing total cost of care, enhancing medication adherence, and improving outcomes under value-based care arrangements.
Asembia 2024 speaker Bill...
07/26/2024
First Report Managed Care
News
Meta-Analysis Shows Bidirectional Link Between Psoriasis and Asthma
07/26/2024
A recent systematic review and meta-analysis spanning 12.4 million patients found a significant bidirectional association between psoriasis and asthma. Researchers published their findings online in BMC Pulmonary Medicine.
A recent systematic review and meta-analysis spanning 12.4 million patients found a significant bidirectional association between psoriasis and asthma. Researchers published their findings online in BMC Pulmonary Medicine.
A recent systematic review and...
07/26/2024
First Report Managed Care
News
HIV Cases Rise Among Gay Latinos
07/24/2024
As HIV rates continue to rise among Latino gay and bisexual men, health policy advocates stress the need for more federal assistance for HIV treatment and prevention in this community.
As HIV rates continue to rise among Latino gay and bisexual men, health policy advocates stress the need for more federal assistance for HIV treatment and prevention in this community.
As HIV rates continue to rise...
07/24/2024
First Report Managed Care
Quiz
COPD and RSV Infection Incidences
07/23/2024
True or False: Patients with chronic obstructive pulmonary disease (COPD) have a lower incidence of RSV infection compared to the general population because treatments for COPD also alleviate the symptoms of RSV.
True or False: Patients with chronic obstructive pulmonary disease (COPD) have a lower incidence of RSV infection compared to the general population because treatments for COPD also alleviate the symptoms of RSV.
True or False: Patients with...
07/23/2024
First Report Managed Care

Advertisement

Advertisement

FRMC Volume 21, Issue 2

Current Issue

June 2024
Volume 21
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement